Chemistry:Magaldrate
| [math]\ce{ [Al^{3+}][Mg^{2+}]2[HO^{-}]7[H2O] }[/math] | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a682683 |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Negligible |
| Metabolism | Nil |
| Excretion | Fecal and renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | AlMg2(OH)7·H2O |
| Molar mass | 212.66 g/mol |
| |
| (verify) | |
Magaldrate (INN) is a common antacid drug that is used for the treatment of duodenal and gastric ulcers, esophagitis from gastroesophageal reflux.
Development
Magaldrat was first synthesized by the German chemist Gunther Hallmann and patented on February 2, 1960, by Byk Gulden Lomberg Chemische Fabrik (Germany).[1] In 1983, the active substance was registered as the original drug Riopan.[2]
Available forms
Magaldrate is available in the form of oral suspension or tablets.
Pharmacology
Magaldrate is a hydroxymagnesium aluminate complex that is converted rapidly by gastric acid into Mg(OH)2 and Al(OH)3, which are absorbed poorly and thus provide a sustained antacid effect.[3]
Interactions and adverse reactions
Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.
References
- ↑ Hallmann G, "Process for the preparation of magnesium aluminate hydrate, and therapeutic agents so produced", US patent 2923660, issued 1960-02-02, assigned to Byk Gulden Lomberg Chem. Fab.
- ↑ Fachinfo Riopan Magen Tabletten, Stand Dezember 2014.
- ↑ Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed.
 |  |
